2 studies found for:    PROSTATE CANCER, HEREDITARY, 2
Show Display Options
Rank Status Study
1 Active, not recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Hereditary Breast/Ovarian Cancer (BRCA1, BRCA2);   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Pancreatic Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Recurrent Prostate Cancer;   Triple-negative Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib;   Other: pharmacological study;   Other: laboratory biomarker analysis
2 Recruiting Prostate Cancer Screening Among Men With High Risk Genetic Predisposition
Conditions: BRCA1 Syndrome;   BRCA2 Syndrome;   Lynch Syndrome
Interventions: Procedure: PSA and free to total PSA;   Other: IPSS questionnaire;   Procedure: DRE (Digital Rectal Examination );   Procedure: urine flow and residual;   Procedure: a multiparametric prostate MRI;   Procedure: trans-rectal ultra-sound guided prostate biopsy

Indicates status has not been verified in more than two years